HER2-POSITIVE MUSCLE-INVASIVE BLADDER CANCER
Clinical trials for HER2-POSITIVE MUSCLE-INVASIVE BLADDER CANCER explained in plain language.
Never miss a new study
Get alerted when new HER2-POSITIVE MUSCLE-INVASIVE BLADDER CANCER trials appear
Sign up with your email to follow new studies for HER2-POSITIVE MUSCLE-INVASIVE BLADDER CANCER, keep track of the ones that matter, and come back to a personal dashboard instead of checking manually.
By submitting, you agree to our Terms of use
-
Promising combo aims to shrink bladder tumors before surgery
Disease control Not yet recruitingThis study tests whether combining two drugs (trastuzumab rezetecan and camrelizumab) before surgery can improve outcomes for people with a certain type of muscle-invasive bladder cancer (HER2-positive). About 44 adults will receive the treatment to see if it helps eliminate canc…
Matched conditions: HER2-POSITIVE MUSCLE-INVASIVE BLADDER CANCER
Phase: PHASE2 • Sponsor: Sheng Tai • Aim: Disease control
Last updated Jun 27, 2026 13:07 UTC
-
New drug duo aims to save bladders in HER2-positive cancer patients
Disease control Not yet recruitingThis phase 2 trial tests two drugs—disitamab vedotin and toripalimab—as a way to treat HER2-positive muscle-invasive bladder cancer without removing the bladder. About 60 adults with locally advanced cancer will receive different cycles of the combination. The main goal is to see…
Matched conditions: HER2-POSITIVE MUSCLE-INVASIVE BLADDER CANCER
Phase: PHASE2 • Sponsor: Renmin Hospital of Wuhan University • Aim: Disease control
Last updated Jun 26, 2026 13:16 UTC